News

How Abbott Laboratories Stock Has Been Performing Abbott Laboratories has attracted fresh attention from investors after a recent rebound in its share price, raising the question of whether the current level reflects fair value or an opportunity. Over the past week the stock gained 6.5%, with a 9.9% rise over the last 30 days, although returns since the start of the year are down 24.2% and the one year return is down 28.5%. This gives important context to the recent strength. These moves have...

Abbott Laboratories is scheduled to report its second-quarter results in July, and analysts expect a single-digit earnings rise.

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

Abbott Laboratories (NYSE:ABT) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth. Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the ... Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Bu

Backed by bullish positioning from 73 hedge funds and analyst expectations of 30.93% upside, Abbott Laboratories (NYSE:ABT) ranks among the top stocks to buy for financial stability. Abbott Laboratories (NYSE:ABT) has drawn mixed analyst signals recently, with one firm seeing hidden value in a breakup scenario while another trimmed its outlook on broader sector concerns. […]

Abbott Laboratories (NYSE:ABT) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring. Pillar One: Durability Built Into the Business Model Abbott’s revenue flows from four distinct segments ... Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat

MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.

ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.

Overseas markets are central to MiniMed’s business, accounting for 70% of reported net sales in the company’s 2026 financial year.

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Similac, Abbott Laboratories' (NYSE:ABT) infant nutrition brand, has launched its "Love Without Measure" initiative. The campaign focuses on easing social media pressures on young and Gen Z parents and promoting a more supportive online community. Similac is partnering with motherhood experts and social media influencers to highlight mental health, inclusivity, and judgment free parenting. For investors following Abbott Laboratories, the move highlights how the company is engaging with...

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.

July earnings matter, but long-term growth matters more.

Abbott Laboratories (NYSE:ABT) is included among the Dividend Stock Portfolio: Top 10 Stocks to Buy According to Reddit. On June 17, Citi reiterated its Buy rating on Abbott Laboratories (NYSE:ABT). It said that the company’s individual businesses may be worth more than the market currently values the company as a whole. According to the firm’s […]

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

FiberSense’s device uses optical sensor technology to monitor the concentration of glucose in the subcutaneous tissue fluid.

ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.

While STERIS has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Earlier this month, Abbott’s board declared a quarterly dividend of US$0.63 per share, payable on August 17, 2026, to shareholders of record on July 15, marking the company’s 410th consecutive quarterly payout since 1924. At the same time, Abbott secured CE Mark for its Libre Duo dual glucose‑ketone sensors and expanded a commercialization agreement with MiniMed, underscoring how its diabetes technology is targeting diabetic ketoacidosis risks highlighted by recent company-backed...

Abbott Laboratories (NYSE:ABT) is one of the Best Bargain Stocks to Buy in June. On June 12, BofA analyst Travis Steed reduced the firm’s price objective on the company’s stock to $102 from $120 and maintained a “Buy” rating on the shares. The analyst took a more conservative view on 2027 med-tech company estimates. This is because […]

Abbott Laboratories (NYSE:ABT) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Abbott Laboratories (NYSE:ABT) announced new data showing that diabetic ketoacidosis, or DKA, “remains an important” but often undetected health concern for people with both Type 1 and Type 2 diabetes. The findings, shared at the American Diabetes […]

Abbott (ABT) closed the most recent trading day at $88.18, moving 1.64% from the previous trading session.

Insightful Moves in Elfun Trusts (Trades, Portfolio)' First Quarter 2026 N-PORT Filing

Abbott Laboratories (NYSE:ABT) is a deep value stock to invest in now. On June 3, Abbott Laboratories (NYSE:ABT) entered into an expanded agreement with MiniMed. The two are joining forces to commercialize dual glucose-ketone sensors for integration with MiniMed smart dosing systems. The monitoring sensors under commercialization are designed to enable real-time detection of rising […]

Abbott Laboratories (NYSE:ABT) secured European CE Mark approval for Libre Duo, described as the world's first dual glucose and ketone continuous monitoring sensor. The company presented new data at the American Diabetes Association's 2026 Scientific Sessions on diabetic ketoacidosis risk and outcomes from its Healthy Food Rx program for people with type 2 diabetes. The American Cancer Society reaffirmed Abbott's Cologuard and Cologuard Plus as preferred options in updated US colorectal...

In the most recent trading session, Abbott (ABT) closed at $89.17, indicating a -2.28% shift from the previous trading day.

ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects.

MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.